• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    France Point of Care Molecular Diagnostics Market

    ID: MRFR/MED/49959-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    France Point-of-care Molecular Diagnostics Market Research Report By Product Type (PCR Tests, Nucleic Acid Amplification Tests, Microarray, Next-Generation Sequencing, Other Genetic Tests), By Application (Infectious Diseases, Genetic Testing, Cancer Diagnosis, Metabolic Disorders), By End-use (Hospitals, Diagnostic Laboratories, Home Care Settings, Outpatient Clinics), and By Technology (Isothermal Amplification, Polymerase Chain Reaction, Sanger Sequencing, CRISPR Technology)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    France Point of Care Molecular Diagnostics Market Research Report- Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    France Point of Care Molecular Diagnostics Market Summary

    The France Point-of-care Molecular Diagnostics market is projected to grow significantly from 337.5 million USD in 2024 to 810 million USD by 2035.

    Key Market Trends & Highlights

    France Point-of-care Molecular Diagnostics Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate of 8.28 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 810 million USD, indicating robust growth potential.
    • In 2024, the market is valued at 337.5 million USD, reflecting a strong foundation for future expansion.
    • Growing adoption of point-of-care testing due to increasing demand for rapid diagnostic solutions is a major market driver.

    Market Size & Forecast

    2024 Market Size 337.5 (USD Million)
    2035 Market Size 810 (USD Million)
    CAGR (2025-2035) 8.28%

    Major Players

    QIAGEN, F. Hoffmann La Roche, Acon Laboratories, Diagnostics Bio, Roche, Genomic Health, Hologic, Becton Dickinson, Cepheid, Abbott, Siemens Healthineers, bioMerieux, Thermo Fisher Scientific, Innoscreen

    France Point of Care Molecular Diagnostics Market Trends

    A changing healthcare environment is driving a number of noteworthy trends in the Point-of-Care Molecular Diagnostics market in France. The growing focus on personalised medicine, bolstered by government programs aimed at improving patient outcomes, is one of the major factors propelling the industry.

    The expansion of point-of-care solutions is being aided by the French government's investments in digital health and real-time diagnostic techniques. This supports quick and precise diagnosis, which is in line with the larger EU health agenda.

    The growing need for home testing options is another noteworthy trend. As healthcare continues to move towards decentralisation, more patients are looking for testing choices that are easy to use and accessible.

    This trend was hastened by the COVID-19 pandemic, which brought attention to the need for quick diagnosis in the management of infectious disorders. In response, the French healthcare system has made it possible for new testing instruments to be approved more quickly, guaranteeing that patients may receive diagnostics on time.

    Technological developments, such the incorporation of machine learning and artificial intelligence into diagnostic procedures, offer opportunities in this sector. More healthcare professionals may choose to use molecular diagnostics as a result of this advancement's potential to improve testing speed and accuracy.

    Furthermore, cooperation between private sector entities and public health organisations might result in creative solutions that tackle particular health issues that the French populace faces.

    The market for point-of-care molecular diagnostics in France is expected to rise significantly as patient awareness of the value of early detection increases. This growth will be fuelled by these changing patterns as well as the government's encouraging framework for improved healthcare delivery.

    France Point-of-care

    France Point of Care Molecular Diagnostics Market Drivers

    Market Segment Insights

    Point-of-care

    The France Point-of-care Molecular Diagnostics Market showcases a diverse array of Product Types, each contributing significantly to the overall landscape and addressing various healthcare needs. Among these, PCR Tests have emerged as a cornerstone for rapid and accurate pathogen detection, particularly in infectious diseases, making them integral in clinical and emergency settings.

    Nucleic Acid Amplification Tests represent another pivotal segment, facilitating sensitive detection of genetic material, which is crucial for early diagnosis and personalized treatment strategies.

    Microarrays offer a comprehensive platform that enables simultaneous analysis of multiple genes, proving advantageous for complex conditions such as cancer or genetic disorders, thus enhancing precision medicine initiatives in France.

    Next-Generation Sequencing stands out for its ability to conduct in-depth genomic analyses, which are vital for understanding hereditary diseases and tailoring therapies. Other Genetic Tests encompass a range of specialized procedures that cater to both inherited and acquired conditions, emphasizing the growing trend of personalized healthcare.

    Point-of-care

    The France Point-of-care Molecular Diagnostics Market, under the Application segment, is experiencing notable activity across various fields, reflecting the growing emphasis on rapid and accurate diagnostics. Infectious Diseases dominate this segment, driven by the increasing prevalence of infectious diseases and the necessity for prompt diagnosis, particularly emphasized during health crises.

    Genetic Testing plays a vital role in enabling personalized medicine, with advancements in technology improving accessibility for patients seeking genomic insights. Cancer Diagnosis is increasingly significant due to the rising cancer incidence in France, making early detection a priority for healthcare systems.

    Furthermore, the segment addressing Metabolic Disorders gains traction as awareness about metabolic health impacts broadens, fostering demand for efficient testing methods.

    Overall, the segmentation within the France Point-of-care Molecular Diagnostics Market illustrates a landscape characterized by innovation, driven by the need for time-sensitive and precise diagnostic solutions in critical health conditions. This is further supported by the ongoing investments in Research and Development to enhance diagnostic technologies and healthcare outcomes across the region.

    Point-of-care

    The France Point-of-care Molecular Diagnostics Market demonstrates a diverse and robust segmentation in its End-use sector, notably encompassing Hospitals, Diagnostic Laboratories, Home Care Settings, and Outpatient Clinics. Hospitals play a critical role, equipped with advanced technologies to deliver immediate results, thereby enhancing clinical decision-making.

    Diagnostic Laboratories are essential as well, serving a high volume of tests and supporting research initiatives, which boost overall accuracy and efficiency. Home Care Settings are increasingly significant, driven by the rising trend of personalized healthcare and patient convenience, allowing for testing in a comfortable environment.

    Outpatient Clinics are also integral, addressing the need for rapid diagnostics without requiring extensive hospital resources, thus improving access to essential healthcare services. The growing demand for rapid and accurate testing solutions underscores the significance of these settings in the overall market landscape.

    Furthermore, factors such as an aging population and the increasing incidence of infectious diseases in France are expected to drive market growth, resulting in a strategic focus on improving diagnostic capabilities across all these sectors. The collective evolution of these segments reflects the dynamic nature and increasing importance of the France Point-of-care Molecular Diagnostics Market.

    Point-of-care

    The France Point-of-care Molecular Diagnostics Market showcases a diverse range of technologies that cater to the growing demand for rapid and accurate diagnostic solutions. Key technologies include Isothermal Amplification, which has gained traction due to its ability to detect nucleic acids at a constant temperature, allowing for easy integration into remote healthcare settings.

    Polymerase Chain Reaction (PCR) has historically dominated the market, primarily because of its high sensitivity and specificity, making it a staple in infectious disease diagnostics. Sanger Sequencing remains significant as it provides reliable results for confirming findings from other methods, particularly in personalized medicine and genetic analysis.

    Meanwhile, CRISPR Technology is emerging as a game-changer, enabling rapid diagnostics with its precise gene-editing capabilities.

    Together, these technologies contribute to the improvement of healthcare outcomes in France, addressing the increasing need for efficient, point-of-care testing solutions that can be readily deployed in various settings, including hospitals and community health centers.

    Get more detailed insights about France Point of Care Molecular Diagnostics Market Research Report- Forecast to 2035

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The competitive insights of the France Point-of-care Molecular Diagnostics Market reveal a landscape that is rapidly evolving due to technological advancements and an increasing demand for rapid diagnostic solutions. The market is characterized by significant investments in research and development, leading to innovative product offerings that enhance the speed and accuracy of disease detection.

    The competition is shaped by various factors, including the integration of advanced molecular techniques, regulatory developments, and partnerships that aim to improve the efficiency of healthcare delivery. As healthcare systems embrace point-of-care testing, the significance of localized diagnostics becomes increasingly apparent, enabling timely decision-making and better patient outcomes.

    Key players in this market are focusing on expanding their portfolio and enhancing their service offerings to retain a competitive edge. QIAGEN has established a strong foothold in the France Point-of-care Molecular Diagnostics Market, focusing on delivering high-quality molecular testing solutions.

    The company is well-regarded for its comprehensive range of products that cater to various diagnostics needs, including infectious diseases and oncology. QIAGEN's innovative technologies, such as its proprietary extraction and assay platforms, facilitate efficient sample processing and accuracy in results, positioning the firm favorably among healthcare providers.

    This strength is complemented by QIAGEN's commitment to regulatory compliance, which ensures that its products meet the stringent requirements of the French healthcare system. The company's strategic collaborations and partnerships with local health authorities further bolster its market presence and drive the adoption of its diagnostic solutions across diverse clinical settings in France.

    F. HoffmannLa Roche holds a significant position within the France Point-of-care Molecular Diagnostics Market, offering an array of key products and services geared towards molecular testing. The company's diagnostic portfolio includes cutting-edge solutions that streamline the detection of various diseases, including infectious diseases and genetic disorders.

    Its robust infrastructure in France supports a reliable distribution network and enhances accessibility to its advanced testing capabilities. Strengths of F. HoffmannLa Roche lie in its commitment to innovation, coupled with a strong focus on research and development that continually fuels the introduction of state-of-the-art diagnostic tools.

    The company's proactive approach in engaging with French regulatory bodies and continuous investment in local partnerships illustrate its dedication to addressing the evolving needs of the healthcare landscape.

    Mergers and acquisitions have also played a crucial role in expanding F. HoffmannLa Roche's capabilities, enabling them to integrate complementary technologies and enhance their market offerings in the point-of-care diagnostics arena within France.

    Key Companies in the France Point of Care Molecular Diagnostics Market market include

    Industry Developments

    The France Point-of-care Molecular Diagnostics Market has witnessed notable developments in recent months. In October 2023, Abbott launched a new molecular diagnostic device aimed at enhancing rapid testing capabilities across various healthcare settings in France.

    Concurrently, Cepheid introduced a significant upgrade to its GeneXpert system, improving user accessibility and operational efficiency. In terms of market dynamics, F. Hoffmann-La Roche and QIAGEN reported increased revenues driven by heightened demand for COVID-19 related testing solutions, contributing to a 15% growth in the market valuation in 2023.

    Acon Laboratories and bioMerieux are also gaining traction, focusing on innovations that cater to infectious disease diagnosis in point-of-care settings. In the realm of mergers and acquisitions, Thermo Fisher Scientific has been involved in discussions for potential partnerships with local firms to bolster its market presence as of September 2023.

    The growing emphasis on decentralized testing solutions reflects the French government's commitment to enhancing healthcare accessibility, further driving investments in molecular diagnostics technologies. These developments underscore a rapidly evolving landscape with significant potential for market expansion in France, particularly against the backdrop of ongoing public health initiatives.

    France Point-of-care

    Market Segmentation

    Point-of-care Molecular Diagnostics Market End-useOutlook

    • Hospitals
    • Diagnostic Laboratories
    • Home Care Settings
    • Outpatient Clinics

    Point-of-care Molecular Diagnostics Market Technology Outlook

    • Isothermal Amplification
    • Polymerase Chain Reaction
    • Sanger Sequencing
    • CRISPR Technology

    Point-of-care Molecular Diagnostics Market Application Outlook

    • Infectious Diseases
    • Genetic Testing
    • Cancer Diagnosis
    • Metabolic Disorders

    Point-of-care Molecular Diagnostics Market Product Type Outlook

    • PCR Tests
    • Nucleic Acid Amplification Tests
    • Microarray
    • Next-Generation Sequencing
    • Other Genetic Tests

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 311.58(USD Million)
    MARKET SIZE 2024 337.5(USD Million)
    MARKET SIZE 2035 810.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 8.284% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED QIAGEN, F. HoffmannLa Roche, Acon Laboratories, Diagnostics Bio, Roche, Genomic Health, Hologic, Becton Dickinson, Cepheid, Abbott, Siemens Healthineers, bioMerieux, Thermo Fisher Scientific, Innoscreen
    SEGMENTS COVERED Product Type, Application, End Use, Technology
    KEY MARKET OPPORTUNITIES Increased demand for rapid testing, Expansion of telemedicine services, Growing focus on infectious disease management, Advancements in molecular diagnostic technologies, Rising prevalence of chronic diseases
    KEY MARKET DYNAMICS Rise in chronic diseases, Growing demand for rapid testing, Technological advancements in diagnostics, Increased healthcare expenditure, Regulatory support for innovations
    COUNTRIES COVERED France

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    What is the expected market size of the France Point of Care Molecular Diagnostics Market in 2024?

    The market is expected to be valued at 337.5 million USD in 2024.

    What is the forecasted market size in the France Point of Care Molecular Diagnostics Market by 2035?

    By 2035, the market is expected to reach a valuation of 810.0 million USD.

    What is the expected compound annual growth rate (CAGR) for the France Point of Care Molecular Diagnostics Market from 2025 to 2035?

    The market is projected to grow at a CAGR of 8.284% from 2025 to 2035.

    Which product type leads the France Point of Care Molecular Diagnostics Market in 2024?

    PCR Tests lead the market with a value of 90.0 million USD in 2024.

    How will the value of Nucleic Acid Amplification Tests change by 2035?

    The value of Nucleic Acid Amplification Tests is expected to increase to 200.0 million USD by 2035.

    Who are the major players in the France Point of Care Molecular Diagnostics Market?

    Key players include QIAGEN, Roche, Abbott, and Siemens Healthineers.

    What is the projected market value of Microarray in 2035?

    The market value of Microarray is anticipated to reach 120.0 million USD by 2035.

    What impact do current global events have on the France Point of Care Molecular Diagnostics Market?

    Current global events may influence market dynamics including growth opportunities and challenges.

    What is the expected market value for Other Genetic Tests in 2024?

    The market value for Other Genetic Tests is projected to be 32.5 million USD in 2024.

    What growth opportunities exist for the France Point of Care Molecular Diagnostics Market?

    Emerging technologies in diagnostics and increased demand for rapid testing present significant growth opportunities.

    1. EXECUTIVE
    2. SUMMARY
    3. Market Overview
    4. Key Findings
    5. Market Segmentation
    6. Competitive Landscape
    7. Challenges and Opportunities
    8. Future Outlook
    9. MARKET INTRODUCTION
    10. Definition
    11. Scope of the study
    12. Research Objective
    13. Assumption
    14. Limitations
    15. RESEARCH
    16. METHODOLOGY
    17. Overview
    18. Data
    19. Mining
    20. Secondary Research
    21. Primary
    22. Research
    23. Primary Interviews and Information Gathering
    24. Process
    25. Breakdown of Primary Respondents
    26. Forecasting
    27. Model
    28. Market Size Estimation
    29. Bottom-Up
    30. Approach
    31. Top-Down Approach
    32. Data
    33. Triangulation
    34. Validation
    35. MARKET
    36. DYNAMICS
    37. Overview
    38. Drivers
    39. Restraints
    40. Opportunities
    41. MARKET FACTOR ANALYSIS
    42. Value chain Analysis
    43. Porter's
    44. Five Forces Analysis
    45. Bargaining Power of Suppliers
    46. Bargaining
    47. Power of Buyers
    48. Threat of New Entrants
    49. Threat
    50. of Substitutes
    51. Intensity of Rivalry
    52. COVID-19
    53. Impact Analysis
    54. Market Impact Analysis
    55. Regional
    56. Impact
    57. Opportunity and Threat Analysis
    58. France
    59. Point of Care Molecular Diagnostics Market, BY Product Type (USD Million)
    60. PCR
    61. Tests
    62. Nucleic Acid Amplification Tests
    63. Microarray
    64. Next-Generation
    65. Sequencing
    66. Other Genetic Tests
    67. France
    68. Point of Care Molecular Diagnostics Market, BY Application (USD Million)
    69. Infectious
    70. Diseases
    71. Genetic Testing
    72. Cancer
    73. Diagnosis
    74. Metabolic Disorders
    75. France
    76. Point of Care Molecular Diagnostics Market, BY End Use (USD Million)
    77. Hospitals
    78. Diagnostic
    79. Laboratories
    80. Home Care Settings
    81. Outpatient
    82. Clinics
    83. France Point of Care
    84. Molecular Diagnostics Market, BY Technology (USD Million)
    85. Isothermal
    86. Amplification
    87. Polymerase Chain Reaction
    88. Sanger
    89. Sequencing
    90. CRISPR Technology
    91. Competitive Landscape
    92. Overview
    93. Competitive
    94. Analysis
    95. Market share Analysis
    96. Major
    97. Growth Strategy in the Point of Care Molecular Diagnostics Market
    98. Competitive
    99. Benchmarking
    100. Leading Players in Terms of Number of Developments
    101. in the Point of Care Molecular Diagnostics Market
    102. Key
    103. developments and growth strategies
    104. New Product Launch/Service
    105. Deployment
    106. Merger & Acquisitions
    107. Joint
    108. Ventures
    109. Major Players Financial Matrix
    110. Sales
    111. and Operating Income
    112. Major Players R&D Expenditure.
    113. Company
    114. Profiles
    115. QIAGEN
    116. Financial
    117. Overview
    118. Products Offered
    119. Key
    120. Developments
    121. SWOT Analysis
    122. Key
    123. Strategies
    124. F. HoffmannLa Roche
    125. Financial
    126. Overview
    127. Products Offered
    128. Key
    129. Developments
    130. SWOT Analysis
    131. Key
    132. Strategies
    133. Acon Laboratories
    134. Financial
    135. Overview
    136. Products Offered
    137. Key
    138. Developments
    139. SWOT Analysis
    140. Key
    141. Strategies
    142. Diagnostics Bio
    143. Financial
    144. Overview
    145. Products Offered
    146. Key
    147. Developments
    148. SWOT Analysis
    149. Key
    150. Strategies
    151. Roche
    152. Financial
    153. Overview
    154. Products Offered
    155. Key
    156. Developments
    157. SWOT Analysis
    158. Key
    159. Strategies
    160. Genomic Health
    161. Financial
    162. Overview
    163. Products Offered
    164. Key
    165. Developments
    166. SWOT Analysis
    167. Key
    168. Strategies
    169. Hologic
    170. Financial
    171. Overview
    172. Products Offered
    173. Key
    174. Developments
    175. SWOT Analysis
    176. Key
    177. Strategies
    178. Becton Dickinson
    179. Financial
    180. Overview
    181. Products Offered
    182. Key
    183. Developments
    184. SWOT Analysis
    185. Key
    186. Strategies
    187. Cepheid
    188. Financial
    189. Overview
    190. Products Offered
    191. Key
    192. Developments
    193. SWOT Analysis
    194. Key
    195. Strategies
    196. Abbott
    197. Financial
    198. Overview
    199. Products Offered
    200. Key
    201. Developments
    202. SWOT Analysis
    203. Key
    204. Strategies
    205. Siemens Healthineers
    206. Financial
    207. Overview
    208. Products Offered
    209. Key
    210. Developments
    211. SWOT Analysis
    212. Key
    213. Strategies
    214. bioMerieux
    215. Financial
    216. Overview
    217. Products Offered
    218. Key
    219. Developments
    220. SWOT Analysis
    221. Key
    222. Strategies
    223. Thermo Fisher Scientific
    224. Financial
    225. Overview
    226. Products Offered
    227. Key
    228. Developments
    229. SWOT Analysis
    230. Key
    231. Strategies
    232. Innoscreen
    233. Financial
    234. Overview
    235. Products Offered
    236. Key
    237. Developments
    238. SWOT Analysis
    239. Key
    240. Strategies
    241. References
    242. Related
    243. Reports
    244. LIST
    245. OF ASSUMPTIONS
    246. France Point of Care Molecular Diagnostics
    247. Market SIZE ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD Billions)
    248. France
    249. Point of Care Molecular Diagnostics Market SIZE ESTIMATES & FORECAST, BY APPLICATION,
    250. 2035 (USD Billions)
    251. France Point of Care Molecular
    252. Diagnostics Market SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD Billions)
    253. France
    254. Point of Care Molecular Diagnostics Market SIZE ESTIMATES & FORECAST, BY TECHNOLOGY,
    255. 2035 (USD Billions)
    256. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    257. ACQUISITION/PARTNERSHIP
    258. LIST
    259. Of figures
    260. MARKET SYNOPSIS
    261. FRANCE
    262. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ANALYSIS BY PRODUCT TYPE
    263. FRANCE
    264. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ANALYSIS BY APPLICATION
    265. FRANCE
    266. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ANALYSIS BY END USE
    267. FRANCE
    268. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ANALYSIS BY TECHNOLOGY
    269. KEY
    270. BUYING CRITERIA OF POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
    271. RESEARCH
    272. PROCESS OF MRFR
    273. DRO ANALYSIS OF POINT OF CARE MOLECULAR
    274. DIAGNOSTICS MARKET
    275. DRIVERS IMPACT ANALYSIS: POINT OF
    276. CARE MOLECULAR DIAGNOSTICS MARKET
    277. RESTRAINTS IMPACT ANALYSIS:
    278. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
    279. SUPPLY / VALUE
    280. CHAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
    281. POINT
    282. OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2025 (% SHARE)
    283. POINT
    284. OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019 TO 2035 (USD Billions)
    285. POINT
    286. OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 (% SHARE)
    287. POINT
    288. OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019 TO 2035 (USD Billions)
    289. POINT
    290. OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USE, 2025 (% SHARE)
    291. POINT
    292. OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USE, 2019 TO 2035 (USD Billions)
    293. POINT
    294. OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 (% SHARE)
    295. POINT
    296. OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019 TO 2035 (USD Billions)
    297. BENCHMARKING
    298. OF MAJOR COMPETITORS

    France Point of Care Molecular Diagnostics Market Segmentation

     

    • Point of Care Molecular Diagnostics Market By Product Type (USD Million, 2019-2035)

      • PCR Tests
      • Nucleic Acid Amplification Tests
      • Microarray
      • Next-Generation Sequencing
      • Other Genetic Tests

     

    • Point of Care Molecular Diagnostics Market By Application (USD Million, 2019-2035)

      • Infectious Diseases
      • Genetic Testing
      • Cancer Diagnosis
      • Metabolic Disorders

     

    • Point of Care Molecular Diagnostics Market By End Use (USD Million, 2019-2035)

      • Hospitals
      • Diagnostic Laboratories
      • Home Care Settings
      • Outpatient Clinics

     

    • Point of Care Molecular Diagnostics Market By Technology (USD Million, 2019-2035)

      • Isothermal Amplification
      • Polymerase Chain Reaction
      • Sanger Sequencing
      • CRISPR Technology

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027